Anandamide receptors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Di Marzo, 1995, Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’, Prostaglandins Leukot Essent Fatty Acids, 53, 1, 10.1016/0952-3278(95)90077-2
Di Marzo, 1998, ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance, Biochim Biophys Acta, 1392, 153, 10.1016/S0005-2760(98)00042-3
Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946, 10.1126/science.1470919
Mechoulam, 1995, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem Pharmacol, 50, 83, 10.1016/0006-2952(95)00109-D
Sugiura, 1995, 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain, Biochem Biophys Commun, 215, 89, 10.1006/bbrc.1995.2437
Hanus, 2001, 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor, Proc Natl Acad Sci USA, 98, 3662, 10.1073/pnas.061029898
Mechoulam, 1995, 233
Pertwee, 1999, Pharmacology of cannabinoid receptor ligands, Curr Med Chem, 6, 635, 10.2174/0929867306666220401124036
Khanolkar, 2000, Molecular probes for the cannabinoid receptors, Chem Phys Lipids, 108, 37, 10.1016/S0009-3084(00)00186-9
Di Marzo, 1999, Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids, Curr Med Chem, 6, 721, 10.2174/0929867306666220401141630
IDi Marzo, 2001, Endocannabinoids Part I: Molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors, Emerging Therapeutic Targets, 5, 241, 10.1517/14728222.5.2.241
Di Marzo, 2000, Levels, metabolism and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain, J Neurochem, 75, 2434, 10.1046/j.1471-4159.2000.0752434.x
Adams, 1998, Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain, J Pharmacol Exp Ther, 284, 1209
Ledent, 1999, Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice, Scienze, 283, 401, 10.1126/science.283.5400.401
Zimmer, 1999, Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice, Proc Natl Acad Sci USA, 96, 5780, 10.1073/pnas.96.10.5780
Wiley, 2000, Influence of phenylmethylsulfonyl fluoride on anandamide brain levels and pharmacological effects, Life Sci, 67, 1573, 10.1016/S0024-3205(00)00749-9
Cravatt, 2001, Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase, Proc Natl Acad Sci USA, 98, 9371, 10.1073/pnas.161191698
Souilhac, 1995, Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice, Pharmacol Biochem Behav, 51, 3, 10.1016/0091-3057(94)00396-Z
Calignano, 2001, Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide, Eur J Pharmacol, 419, 191, 10.1016/S0014-2999(01)00988-8
Jarai, 2000, Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice, Hypertension, 35, 679, 10.1161/01.HYP.35.2.679
Calignano, 1997, Inhibition of intestinal motility by anandamide, an endogenous cannabinoid, Eur J Pharmacol, 340, R7
Kimura, 1998, Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor, Biol Pharm Bull, 21, 224, 10.1248/bpb.21.224
Lagalwar, 1999, Anandamides inhibit binding to the muscarinic acetylcholine receptor, J Mol Neurosci, 13, 55, 10.1385/JMN:13:1-2:55
Christopoulos, 2001, Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors, Brain Res, 915, 70, 10.1016/S0006-8993(01)02825-6
Sagan, 1999, Anandamide and WIN 55212-2 inhibit cyclic AMP formation through g-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes, Eur J Neurosci, 11, 691, 10.1046/j.1460-9568.1999.00480.x
Breivogel, 2001, Evidence for a new G-protein-coupled cannabinoid receptor in mouse brain, Mol Pharmacol, 60, 155, 10.1124/mol.60.1.155
Monory, 2001, Nonconventional cannabinoid stimulated [35S]GTPγS binding in the CB1 knockout mice, Int Cannabinoid Res Soc Symposium, 63
Hajos, 2001, Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus, Neuroscience, 106, 1, 10.1016/S0306-4522(01)00287-1
Wagner, 1999, Mesenteric vasodilation mediated by endothelial anandamide receptors, Hypertension, 33, 429, 10.1161/01.HYP.33.1.429
Jarai, 1999, Cannabinoid induced mesenteric vasodilatation through an endothelial site distinct from CB1 or CB2 receptors, Proc Natl Acad Sci USA, 96, 14136, 10.1073/pnas.96.24.14136
Melck, 1999, Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptor, Biochem Biophys Res Commun, 262, 275, 10.1006/bbrc.1999.1105
Di Marzo, 2000, Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide, Eur J Pharmacol, 406, 363, 10.1016/S0014-2999(00)00687-7
Melck, 2000, Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation, Endocrinology, 141, 118, 10.1210/endo.141.1.7239
Di Marzo, V. Jarai, Z. Bisogno, T. Kunos, G. Vasodilator activity of arvanil (N-arachidonoyl-vanillyl-amide), a novel “hybrid” activator nof vanilloid and cannabinoid receptors, Proceedings of the 11th International Conference on Advances in prostaglandin and leukotriene research, 2000, 93
Di Marzo, 2001, Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues, Eur J Pharmacol, 420, 123, 10.1016/S0014-2999(01)01012-3
Di Marzo, 2001, Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor ‘hybrid’ ligands, Biochem Biophys Res Commun, 281, 444, 10.1006/bbrc.2001.4354
Di Marzo, 2002, A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid, J Pharmacol Exp Ther, 10.1124/jpet.300.3.984
Gebremedhin, 1999, Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inibhit L-type Ca2+ channel current, Am J Physiol, 276, H2085
Johnson, 1993, Isolation, identification and synhesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding, Prostaglandins Leukot Essent Fatty Acids, 48, 429, 10.1016/0952-3278(93)90048-2
Shimasue, 1996, Effects of anandamide and arachidonic acid on specific binding of (+) -PN200-110, diltiazem and (−) -desmethoxyverapamil to L-type Ca2+ channel, Eur J Pharmacol, 296, 347, 10.1016/0014-2999(95)00826-8
Jarrahian, 1997, Arachidonylethanolamide (anandamide) binds with low affinity to dihydropyridine binding sites in brain membranes, Prostaglandins Leukot Essent Fatty Acids, 57, 551, 10.1016/S0952-3278(97)90559-7
Venance, 1995, Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes, Nature, 372, 590, 10.1038/376590a0
Boger, 1999, Arachidonic acid amide inhibitors of gap junction cell-cell communication, Bioorg Med Chem Lett, 9, 1151, 10.1016/S0960-894X(99)00148-1
Hampson, 1998, Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission, J Neurochem, 70, 671, 10.1046/j.1471-4159.1998.70020671.x
Poling, 1996, Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels, Neuropharmacology, 35, 983, 10.1016/0028-3908(96)00130-X
Maingret, 2001, The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1, EMBO J, 20, 47, 10.1093/emboj/20.1.47
Van den Bossche, 2000, Influence of cannabinoids on the delayed rectifier in freshly dissociated smooth muscle cells of the rat aorta, Br J Pharmacol, 131, 85, 10.1038/sj.bjp.0703521
Caterina, 1997, The capsaicin receptor: a heat-activatedion channel in the pain pathway, Nature, 389, 816, 10.1038/39807
Holzer, 1991, Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons, Pharmacol Rev, 43, 143
Szallasi, 1990, Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor, Life Sci, 47, 1399, 10.1016/0024-3205(90)90518-V
Guo, 1999, Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3, purinoceptor and IB4 binding sites, Eur J Neurosci, 11, 946, 10.1046/j.1460-9568.1999.00503.x
Tominaga, 1998, The cloned capsaicin receptor integrates multiple pain-producing stimuli, Neuron, 21, 531, 10.1016/S0896-6273(00)80564-4
Davis, 2000, Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia, Nature, 405, 183, 10.1038/35012076
Caterina, 2000, Impaired nociception and pain sensation in mice lacking the capsaicin receptor, Science, 288, 306, 10.1126/science.288.5464.306
Dray, 1992, Neuropharmacological mechanisms of capsaicin and related substances, Biochem Pharmacol, 44, 611, 10.1016/0006-2952(92)90393-W
Mezey, 2000, Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human, Proc Natl Acad Sci USA, 97, 3655, 10.1073/pnas.97.7.3655
Hayes, 2000, Cloning and functional expression of a human orthologue of rat vanilloid receptor—1, Pain, 88, 205, 10.1016/S0304-3959(00)00353-5
Cortright, 2001, The tissue distribution and functional characterization of human VR1, Biochem Biophys Res Commun, 281, 1183, 10.1006/bbrc.2001.4482
Kwak, 1998, A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin-like substance, Neuroscience, 86, 619, 10.1016/S0306-4522(98)00012-8
Szallasi, 2000, New perspectives on enigmatic vanilloid receptors, Trends Neurosci, 23, 491, 10.1016/S0166-2236(00)01630-1
Di Marzo, 1998, Interactions between synthetic vanilloids and the endogenous cannabinoid system, FEBS Lett, 436, 449, 10.1016/S0014-5793(98)01175-2
Beltramo, 1999, Anandamide transport inhibition by the vanilloid agonist olvanil, Eur J Pharmacol, 364, 75, 10.1016/S0014-2999(98)00821-8
Richardson, 1998, Antihyperalgesic effects of spinal cannabinoids, Eur J Pharmacol, 345, 145, 10.1016/S0014-2999(97)01621-X
Zygmunt, 1999, Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide, Nature, 400, 452, 10.1038/22761
Smart, 2000, The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1), Br J Pharmacol, 129, 227, 10.1038/sj.bjp.0703050
Szolcsanyi, 2000, Anandamide and the question of its functional role for activation of capsaicin receptors, Trends Pharmacol Sci, 21, 203, 10.1016/S0165-6147(00)01484-X
Vanheel, 2001, Regional differences in anandamide- and, methanandamide- induced membrane potential changes in rat mesenteric arteries, J Pharmacol Exp Ther, 296, 322
Smith, 2001, Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat, Br J Pharmacol, 134, 655, 10.1038/sj.bjp.0704296
Tucker, 2001, The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways, Br J Pharmacol, 132, 1127, 10.1038/sj.bjp.0703906
De Petrocellis, 2001, The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase, J Neurochem, 77, 1660, 10.1046/j.1471-4159.2001.00406.x
Craib, 2001, A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus, Br J Pharmacol, 134, 30, 10.1038/sj.bjp.0704223
Calignano, 2000, Bidirectional control of airway responsiveness by endogenous cannabinoids, Nature, 408, 96, 10.1038/35040576
Ross, 2001, Structure–activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens, Br J Pharmacol, 132, 631, 10.1038/sj.bjp.0703850
Mang, 2001, Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors, Br J Pharmacol, 134, 161, 10.1038/sj.bjp.0704220
Tognetto, 2001, Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation, J Neurosci, 21, 1104, 10.1523/JNEUROSCI.21-04-01104.2001
Gauldie, 2001, Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints, Br J Pharmacol, 132, 617, 10.1038/sj.bjp.0703890
Harris, 2000, Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo, Neuroreport, 11, 2817, 10.1097/00001756-200008210-00041
Farquhar-Smith, 2000, Cannabinoid CB(1) receptor expression in rat spinal cord, Mol Cell Neurosci, 15, 510, 10.1006/mcne.2000.0844
Ahluwalia, 2000, Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons, Neuroscience, 100, 685, 10.1016/S0306-4522(00)00389-4
Maejima, 2001, Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors, Neuron, 31, 463, 10.1016/S0896-6273(01)00375-0
Davies, 2001, Actions of putative endogenous cannabinoids on synaptic transmission in the rat hippocampal slice, Neuropharmacology, 41, 1000, 10.1016/S0028-3908(01)00145-9
Maccarone, 2000, Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors, J Biol Chem, 275, 31 938, 10.1074/jbc.M005722200
Jacobsson, 2001, Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors, J Phamacol Exp Ther, 299, 951
White, 2001, Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries, Br J Pharmacol, 134, 921, 10.1038/sj.bjp.0704333
Izzo, 2001, Effect of vanilloid drugs on gastrointestinal transit in mice, Br J Pharmacol, 132, 1411, 10.1038/sj.bjp.0703975
Pertwee, 1997, Pharmacology of cannabinoid CB1 and CB2 receptors, Pharmacol Ther, 74, 129, 10.1016/S0163-7258(97)82001-3
De Petrocellis, 2001, The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism, J Biol Chem, 276, 12 856, 10.1074/jbc.M008555200
Jung, 1999, Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel, J Neurosci, 19, 529, 10.1523/JNEUROSCI.19-02-00529.1999
De Petrocellis, 2000, Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity, FEBS Lett, 483, 52, 10.1016/S0014-5793(00)02082-2
Zygmunt, 2000, The anandamide transport inhibitor AM404 activates vanilloid receptors, Eur J Pharmacol, 396, 39, 10.1016/S0014-2999(00)00207-7
Ralevic, 2001, Cannabinoid activation of recombinant and endogenous vanilloid receptors, Eur J Pharmacol, 424, 211, 10.1016/S0014-2999(01)01153-0
Premkumar, 2000, Induction of vanilloid receptor channel activity by protein kinase C, Nature, 408, 985, 10.1038/35050121
Vellani, 2001, Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide, J Physiol, 534, 813, 10.1111/j.1469-7793.2001.00813.x
Lambert, 1999, The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?, Curr Med Chem, 6, 757, 10.2174/0929867306666220401153732
De Petrocellis, 2001, Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors, FEBS Lett, 506, 253, 10.1016/S0014-5793(01)02934-9
Olah, 2001, Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1, J Biol Chem, 276, 31 163, 10.1074/jbc.M101607200
Sprague, 2001, Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide, Eur J Pharmacol, 423, 121, 10.1016/S0014-2999(01)01123-2
Di Marzo, 2001, Anandamide: some like it hot, Trends Pharmacol Sci, 22, 346, 10.1016/S0165-6147(00)01712-0
Garcia, 1998, Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor, J Neurosci, 18, 2834, 10.1523/JNEUROSCI.18-08-02834.1998
Cadas, 1996, Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP, J Neurosci, 16, 3934, 10.1523/JNEUROSCI.16-12-03934.1996
Di Marzo, 1994, Formation and inactivation of endogenous cannabinoid anandamide in central neurons, Nature, 372, 686, 10.1038/372686a0
Hwang, 2000, Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances, Proc Natl Acad Sci USA, 97, 6155, 10.1073/pnas.97.11.6155
Bisogno, 1997, Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes, J Biol Chem, 272, 3315, 10.1074/jbc.272.6.3315
Hansen, 1995, Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture, Biochim Biophys Acta, 1258, 303, 10.1016/0005-2760(95)00134-X
Schmid, 2000, Pathways and mechanisms of N -acylethanolamine biosynthesis: can anandamide be generated selectively?, Chem Phys Lipids, 108, 71, 10.1016/S0009-3084(00)00188-2
Petersen, 1999, N -acylphosphatidylethanolamine-hydrolysing phospholipase D lacks the ability to transphosphatidylate, FEBS Lett, 455, 41, 10.1016/S0014-5793(99)00861-3
Ueda, 2001, Marked activation of the N -acylphosphatidylethanolamine-hydrolyzing phosphodiesterase by divalent cations, Biochim Biophys Acta, 1532, 121, 10.1016/S1388-1981(01)00120-2
De Petrocellis, 1995, Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in vitro, Biochem Mol Biol Int, 36, 1127
Kiss, 1999, Anandamide stimulates phospholipase D activity in PC12 cells but not in NIH 3T3 fibroblasts, FEBS Lett, 447, 209, 10.1016/S0014-5793(99)00295-1
Derocq, 1998, The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines, FEBS Lett, 425, 419, 10.1016/S0014-5793(98)00275-0
Melck, 1999, Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells, FEBS Lett, 463, 235, 10.1016/S0014-5793(99)01639-7
Derkinderen, 2001, Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus, J Neurochem, 77, 957, 10.1046/j.1471-4159.2001.00333.x
Ramer, 2001, R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism, Biochem Biophys Res Commun, 286, 1144, 10.1006/bbrc.2001.5518
Berdyshev, 2001, Cannabinoid-receptor-independent cell signalling by N-acylethanolamines, Biochem J, 360, 67, 10.1042/0264-6021:3600067